COVID-19 ECMO Myths Busted

Abstract

Literature has proven that COVID-19 patients develop pneumonia. Prognosis of this is poor in case of COVID-19 patients developing the following: low lymphocyte count (< 16%) which gets lower with active COVID-19 infection, sedentary lifestyle, obesity, and uncontrolled diabetes mellitus with no exercise. A lot of dilemmas and myths in this nascent COVID-19 pandemic period exist regarding the use of ECMO. Perplexities such as do we treat the COVID-19 patients on ECMO, as a pulmonary ARDS pneumonia, and/or do we need high PEEP or moderate PEEP, during ECMO for this ARDS; are some common COVID-19 ECMO myths which this short review aims to cover in a question-answer format.

Keywords

COVID-19 - ECMO - Myths

Publication History

Article published online:
15 June 2020

• References

• 1 Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med 2020; 8 (04) e24
• 2 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;(e-pub ahead of print). doi: 10.1016/S2213-2600(20)30079-5
• 3 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; (e-pub ahead of print) DOI: 10.1007/s00134-020-05991-x.
• 4 Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Extracorporeal Life Support Organization Task Force on Infections, Extracorporeal Membrane Oxygenation. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med 2011; 12 (03) 277-281
• 5 Risnes I, Wagner K, Ueland T, Mollnes T, Aukrust P, Svennevig J. Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment. Perfusion 2008; 23 (03) 173-178
• 6 Shi J, Chen Q, Yu W. et al. Continuous renal replacement therapy reduces the systemic and pulmonary inflammation induced by venovenous extracorporeal membrane oxygenation in a porcine model. Artif Organs 2014; 38 (03) 215-223
• 7 Holzgraefe B, Broomé M, Kalzén H, Konrad D, Palmér K, Frenckner B. Extracorporeal membrane oxygenation for pandemic H1N1 2009 respiratory failure. Minerva Anestesiol 2010; 76 (12) 1043-1051
• 8 Pinsky MR. The hemodynamic consequences of mechanical ventilation: an evolving story. Intensive Care Med 1997; 23 (05) 493-503
• 9 Beitler JR, Sarge T, Banner-Goodspeed VM. et al. EPVent-2 Study Group. Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-FiO2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 2019; 321 (09) 846-857
• 10 Wiedemann HP, Wheeler AP, Bernard GR. et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354 (24) 2564-2575
• 11 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.1585.
• 12 MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: The potential role of extracorporeal membrane oxygenation. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.2342.
• 13 Bartlett Robert H, Ogino Mark T Brodie, Daniel McMullan, David M, Lorusso Roberto. et al. Initial ELSO Guidance Document: ECMO for COVID-19 patients with severe cardiopulmonary failure. ASAIO Journal 2020; 66 (05) 472-474
• 14 Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19 Lancet. Respir Med 2020;(e-pub ahead of print). doi: 10.1016/S2213-2600(20)30127-2